<qa>  What is the randomized, double-blind, placebo-controlled study?This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of two dosing regimens of MN-001 in patients with Interstitial Cystitis IC. Patients will be screened for study eligibility within seven to nine days of randomization. Eligible patients will be randomized in a 1:1:1 ratio to receive either 500 mg MN-001 bid, 500 mg MN-001 once daily or placebo. Patients will be dispensed study drug beginning at Baseline Visit 2 and will return to the study center for Visit 3 28 days 2 days after Baseline, and Visit 4 56 days 2 days after Baseline, at end of study for safety and efficacy assessments. The patient will be contacted by telephone at Week 6 42 days 2 days after Baseline for an interim follow up. Study drug will be dispensed at Visits 2 and 3. Safety assessments will include adverse events, physical examinations, clinical laboratory testing, and changes in vital signs. Efficacy assessments include percentage of patients at least moderately improved for each treatment group using the patient reported Global Response Assessment GRA see Appendix 1. Secondary assessments include a decrease in bladder painurgency based on change in the patient rating from baseline to endpoint using the GRA see Appendix 1, modified Pelvic Pain and UrgencyFrequency PUF Patient Symptom Scale see Appendix 2 and the OLeary Sant IC Symptom and Problem Index. 